Start of Operations and Effective Accounting Date Termination. Operation of the Profit & Loss Share will be deemed to have commenced as of the Jounce Lead Effective Date. Except as otherwise provided herein, costs and expenses incurred prior to such date are not chargeable to the Profit & Loss Share.
Start of Operations and Effective Accounting Date Termination. (a) Operation of the Profit & Loss Share will be deemed to have commenced as of the Effective Date. Except as otherwise provided herein, costs and expenses incurred prior to such date are not chargeable to the Profit & Loss Share.
(b) Unless otherwise set forth in this Agreement, for reporting and accounting purposes with respect to the Profit & Loss Share, the effective termination date of the Agreement with regard to the last detailing year for all Shared Products and Companion Diagnostics will be the end of the month in which such termination takes place.
Start of Operations and Effective Accounting Date Termination. Operation of the PD-1 Profit & Loss Share will be deemed to have commenced as of the PD-1 Effective Date. Except as otherwise provided herein, costs and expenses incurred prior to such date are not chargeable to the Profit & Loss Share.
Start of Operations and Effective Accounting Date Termination. The P&L Share will commence on the Effective Date.
Start of Operations and Effective Accounting Date Termination. (a) Operation of the Profit & Loss Share will be [***]. Except as otherwise provided herein, costs and expenses incurred prior to such date are [***].
(b) Unless otherwise set forth in this Juno Lead Co-Co Agreement, for reporting and accounting purposes with respect to the Profit & Loss Share, the effective termination date of the Juno Lead Co-Co Agreement with regard to the last detailing year for Juno Program Co-Co Product will be the end of the month in which such termination takes place.
Start of Operations and Effective Accounting Date Termination. (a) Operation of the Profit & Loss Share will be [***]. Except as otherwise provided herein, costs and expenses incurred prior to such date are [***].
(b) Unless otherwise set forth in this Celgene Lead Co-Co Agreement, for reporting and accounting purposes with respect to the Profit & Loss Share, the effective termination date of the Celgene Lead Co-Co Agreement with regard to the last detailing year for Celgene Program Co-Co Product will be the end of the month in which such termination takes place. [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Start of Operations and Effective Accounting Date Termination. The Profit and Loss Share shall commence on the Effective Date. For clarity, Cost of Sales, Eligible Medical Affairs Costs, Commercialization Costs, and Other Operating Expenses incurred prior to Regulatory Approval of each DT Co-Co Product are chargeable to the applicable Profit and Loss Share in accordance with U.S. GAAP principles.
Start of Operations and Effective Accounting Date Termination. Except as otherwise expressly provided in the Agreement, determination of the amounts set forth in this Article 4 will be deemed to commence:
4.7.1 With respect to Preclinical Development Costs and Development Costs, on: the Effective Date of the Agreement, pursuant to Sections 3.1 and/or 3.2 of this Financial Exhibit, as applicable and shall continue until the earlier of (a) the effective date of termination of all Preclinical Development of Compounds under the Preclinical Development Plan and/or all Development of Products under the Co-Development Indication Plan or (b) with respect to a particular Product (or Compound), the date of the applicable Opt-Out Notice issued by Maxygen pursuant to Section 4.1.3(b) of the Agreement, provided that Astellas shall be responsible for the first Ten Million Dollars ($10,000,000) of certain Preclinical Development Costs incurred by the Parties as provided in Section 3.1.2 above of this Financial Exhibit; and
4.7.2 With respect to Distributable Profits: the first time Maxygen exercises its Co-Promotion Option pursuant to Section 5.2 of the Agreement and shall continue until the Commercialization of all Co-Promotion Products ceases or, if earlier with respect to a particular Co-Promotion Product, the date of termination of Maxygen’s Co-Promotion of such Co-Promotion Product pursuant to Section 5.2.9 of the Agreement, provided that Astellas shall have the right to include all Operating Expenses attributable and fairly allocable to such Co-Promotion Product for Co-Development Indications incurred prior to such exercise in the Distributable Profits to be shared by the Parties in accordance with Section 3.3.
Start of Operations and Effective Accounting Date Termination. With respect to Co-Co Product for U.S. Administration, operation of the Profit & Loss Share will be [***] Except as otherwise provided herein, costs and expenses incurred prior to such date are [***].
